Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) Research & Development (2016 - 2025)

Historic Research & Development for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $32.7 million.

  • Macrogenics' Research & Development fell 1932.27% to $32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.1 million, marking a year-over-year decrease of 1808.03%. This contributed to the annual value of $177.2 million for FY2024, which is 636.98% up from last year.
  • Macrogenics' Research & Development amounted to $32.7 million in Q3 2025, which was down 1932.27% from $40.8 million recorded in Q2 2025.
  • In the past 5 years, Macrogenics' Research & Development registered a high of $61.4 million during Q1 2022, and its lowest value of $30.1 million during Q3 2023.
  • In the last 5 years, Macrogenics' Research & Development had a median value of $46.0 million in 2024 and averaged $46.2 million.
  • Per our database at Business Quant, Macrogenics' Research & Development crashed by 3747.59% in 2023 and then soared by 3455.58% in 2024.
  • Macrogenics' Research & Development (Quarter) stood at $55.9 million in 2021, then dropped by 18.26% to $45.7 million in 2022, then grew by 3.72% to $47.4 million in 2023, then fell by 17.87% to $38.9 million in 2024, then decreased by 15.89% to $32.7 million in 2025.
  • Its Research & Development was $32.7 million in Q3 2025, compared to $40.8 million in Q2 2025 and $39.7 million in Q1 2025.